VedaBio, a San Diego, CA-based biotechnology company which specializes in molecular detection, raised over $40M in initial funding.
The round was led by OMX Ventures along with a group of family offices, including Kleinmuntz Associates.
The company intends to use the funds to expand operations, R&D sector and its business reach.
Led by CEO Anurup Ganguli, Chief Medical and Scientific Officer, President, Christine Ginocchio, PhD, MT (ASCP), and Chief Operating Officer Fred Sweeney, PhD, VedaBio provides a platform for near-instant molecular detection of multiplexed analytes, delivering accuracy without the need for target amplification. Its CRISPR Cascade™ operates with a combination of speed and accuracy without the need for target amplification while maintaining PCR-level accuracy.
The company also announced the appointment of leaders Will Harris as VP of Strategic Marketing, Ravi Vijayendran, PhD as SVP of Technical Operations and Quality, Don Masquelier, as VP Engineering, Phil Belgrader, PhD, as VP Systems Integration and Sally Brashear, VP Intellectual Property.
FinSMEs
17/10/2023